Major trial aims to boost survival for kids with aggressive blood cancers
NCT ID NCT07072585
Summary
This study is for children and young adults newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL). It aims to see if adding a targeted drug called daratumumab to standard chemotherapy helps patients live longer without their cancer returning. About 1,700 participants will be randomly assigned to receive either the standard chemo regimen or the standard chemo plus daratumumab.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.